BC Week In Review | Apr 27, 2018
Company News

Lysogene and others partner to develop gene therapy for Fragile X

Lysogene S.A. (Euronext:LYS), SATT Conectus Alsace (Illkirch, France) and Institute of Genetics and Molecular and Cellular Biology (IGBMC) (Illkirch, France) partnered to develop a gene therapy to treat fragile X. SATT Conectus said it provided...
Items per page:
1 - 1 of 1